Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
Response to David Myers
View through CrossRef
David Myers's critique of my proposed Molinist solution to the so-called soteriological problem of evil miscontrues that solution in several key respects. Once those misinterpretations are rectified, it emerges that his proffered critique of my Molinist solution is really quite unrelated to that solution, but constitutes instead an independent argument against the tenability of a religious epistemology of evidentialism in the context of Christian orthodoxy.
Title: Response to David Myers
Description:
David Myers's critique of my proposed Molinist solution to the so-called soteriological problem of evil miscontrues that solution in several key respects.
Once those misinterpretations are rectified, it emerges that his proffered critique of my Molinist solution is really quite unrelated to that solution, but constitutes instead an independent argument against the tenability of a religious epistemology of evidentialism in the context of Christian orthodoxy.
Related Results
Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer
Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer
This randomized clinical trial explores whether hormone intensification at start of androgen deprivation therapy alters selection of androgen receptor (AR) gene alterations within ...
Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support–Free Days in Patients Hospitalized With COVID-19
Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support–Free Days in Patients Hospitalized With COVID-19
IMPORTANCE
Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19.
...
Time and Side-Effect Burden Associated with Red Blood Cell Transfusions in Patients Diagnosed with Transfusion-Dependent β-Thalassemia
Time and Side-Effect Burden Associated with Red Blood Cell Transfusions in Patients Diagnosed with Transfusion-Dependent β-Thalassemia
Abstract
Introduction: β-thalassemia is a genetic blood disorder marked by the inability to produce hemoglobin. Diagnosed primarily in childhood, tra...
Understanding the Association between Red Blood Cell Transfusion Dependency and Humanistic, Psychosocial, and Psychological Burden in Patients with β-Thalassemia from the Patients' Perspective
Understanding the Association between Red Blood Cell Transfusion Dependency and Humanistic, Psychosocial, and Psychological Burden in Patients with β-Thalassemia from the Patients' Perspective
Abstract
Introduction: A recent systematic literature review (Betts M, et al . Clin Ther 2020;42:322-337) perceived that in the past 2 decades, advancements in the t...
Intravenous Vitamin C for Patients Hospitalized With COVID-19
Intravenous Vitamin C for Patients Hospitalized With COVID-19
ImportanceThe efficacy of vitamin C for hospitalized patients with COVID-19 is uncertain.ObjectiveTo determine whether vitamin C improves outcomes for patients with COVID-19.Design...
Phase 2 Study of Tirabrutinib (ONO/GS-4059), a Second-Generation Bruton's Tyrosine Kinase Inhibitor, Monotherapy in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström Macroglobulinemia
Phase 2 Study of Tirabrutinib (ONO/GS-4059), a Second-Generation Bruton's Tyrosine Kinase Inhibitor, Monotherapy in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström Macroglobulinemia
BACKGROUND
Waldenström macroglobulinemia (WM) is a lymphoplasmacytic lymphoma in which bone marrow is infiltrated by immunoglobulin M (IgM)-producing clonal lymphopl...
Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial
Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial
Importance
The longer-term effects of therapies for the treatment of critically ill patients with COVID-19 are unknown.
...
Abstract IA-53: A multi-pronged approach to driving diversity in clinical trials: Bristol Myers Squibb & Bristol Myers Squibb Foundation efforts
Abstract IA-53: A multi-pronged approach to driving diversity in clinical trials: Bristol Myers Squibb & Bristol Myers Squibb Foundation efforts
Abstract
Achieving diversity in clinical trials that reflects the epidemiology of the people and populations affected by diseases and conditions requires an integrat...